California Softens Oil Stance, Leqembi Gains Self-Injection Approval

By / / Breaking News

Key Takeaways

  • California's Energy Commission has postponed the implementation of a controversial profit cap on oil refiners until 2030, signaling a significant shift in the state's regulatory approach amidst concerns over fuel supply stability and rising gasoline prices.
  • Eisai (ESALY) and Biogen (BIIB) have secured U.S. regulatory approval for a new self-injected, subcutaneous form of their Alzheimer's drug, Leqembi (LEQEMBI), promising greater convenience for patients and potentially expanding treatment accessibility.
  • The delay in California's profit cap enforcement is a win for the oil and gas industry, providing "certainty" for investments but drawing criticism from consumer advocates who fear continued price spikes.
  • The new self-injectable Leqembi (LEQEMBI) formulation, with a PDUFA action date of August 31, 2025, is expected to simplify long-term treatment regimens, reducing the need for frequent hospital or infusion center visits.

California's energy regulators have announced a significant policy reversal, delaying the enforcement of a profit cap on oil refiners until 2030. This move by the California Energy Commission (CEC) represents a notable softening of the state's stance toward the oil and gas industry, which has been under intense scrutiny regarding high gasoline prices. The decision comes amid concerns that refinery closures, which have reduced California's refining capacity by approximately 18%, could exacerbate fuel supply issues and lead to even higher prices at the pump.

In separate but equally impactful news, pharmaceutical giants Eisai Co. Ltd. (ESALY) and Biogen Inc. (BIIB) have received U.S. regulatory approval for a new self-injected version of their pioneering Alzheimer’s drug, Leqembi (LEQEMBI). This development is poised to transform the treatment experience for patients with early Alzheimer's disease, offering a more convenient and accessible administration method.

California's Energy Policy Shift

The California Energy Commission's decision to postpone the refinery profit cap, originally part of Governor Gavin Newsom's 2023 law aimed at penalizing excessive oil company profits, is a direct response to the state's ongoing struggle with the highest gasoline prices in the nation. Officials cited the need to stabilize fuel supply, particularly after two refineries announced plans to close, impacting about one-fifth of the state's crude-processing capacity. Experts had warned that imposing penalties could discourage crucial investments in oil production and further escalate fuel costs.

Siva Gunda, Vice Chair of the California Energy Commission, indicated that the profit cap could act as a "deterrent" to refiners investing in the state, underscoring the commission's desire to boost gasoline supply. While the oil industry has welcomed the delay, calling it a source of "certainty," consumer advocacy groups, such as Consumer Watchdog, have criticized the move as a "giveaway to the industry" that could lead to increased price volatility for consumers.

Leqembi's Game-Changing Self-Injection Approval

The U.S. Food and Drug Administration (FDA) has accepted Eisai's (ESALY) Biologics License Application (BLA) for a subcutaneous autoinjector of Leqembi (LEQEMBI), with a Prescription Drug User Fee Act (PDUFA) action date set for August 31, 2025. This approval means patients with mild cognitive impairment or mild dementia due to Alzheimer's disease will soon have the option of weekly at-home injections, significantly reducing the burden of bi-weekly intravenous infusions at hospitals or specialized infusion centers.

This new self-administered formulation is expected to maintain the drug's clinical and biomarker benefits, with studies showing the subcutaneous form cleared 14% more amyloid plaque than the infused version in certain patients. The convenience offered by the autoinjector could lead to higher patient adherence and broader access to treatment. This follows the FDA's earlier approval in January 2025 for a once-every-four-weeks intravenous maintenance dosing of Leqembi (LEQEMBI), further simplifying the treatment pathway after an initial bi-weekly phase. Analysts project Leqembi (LEQEMBI) to generate $5.3 billion in sales for Eisai (ESALY) and Biogen (BIIB) by 2030, highlighting its market potential.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top